Shares of Novo Nordisk (NVO) trading in New York are down $8.93, or 13%, to $60.07 in the pre-market session after the company lowered its sales and operating profit outlook for 2025, citing lower growth expectations for Wegovy in the U.S. obesity market, lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy in select IO markets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk lowers sales and operating profit outlook for 2025
- Lawmakers urge FDA to crack down on knockoff weight loss drugs, Bloomberg says
- Novo Nordisk’s Stock Soars Amid Strategic Moves
- HIMS Lawsuit Alert! Hims & Hers Faces Class Action Lawsuit After Wegovy Scandal
- Avidity, Phathom mentioned as potential takeout targets at Needham